 B. Histologically proven LCH with an activating BRAF mutation. C. Diagnosis of LCH-associated neurodegenerative disease LCH-ND with an activating BRAF mutation in tumor biopsy or in circulating cells and radiologic progression within the past 3 months or radiologic evidence of neurodegeneration with an ataxia rating score 20. 